KR102932817B1 - 인간 면역결핍 바이러스 복제의 억제제로서의 피리도[2,3-d]피리미딘 유도체 - Google Patents

인간 면역결핍 바이러스 복제의 억제제로서의 피리도[2,3-d]피리미딘 유도체

Info

Publication number
KR102932817B1
KR102932817B1 KR1020227001501A KR20227001501A KR102932817B1 KR 102932817 B1 KR102932817 B1 KR 102932817B1 KR 1020227001501 A KR1020227001501 A KR 1020227001501A KR 20227001501 A KR20227001501 A KR 20227001501A KR 102932817 B1 KR102932817 B1 KR 102932817B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
mmol
stirred
reaction
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227001501A
Other languages
English (en)
Korean (ko)
Other versions
KR20220024608A (ko
Inventor
에릭 피 길리스
크리스티아나 이와그우
Original Assignee
비브 헬스케어 유케이 (넘버5) 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비브 헬스케어 유케이 (넘버5) 리미티드 filed Critical 비브 헬스케어 유케이 (넘버5) 리미티드
Publication of KR20220024608A publication Critical patent/KR20220024608A/ko
Application granted granted Critical
Publication of KR102932817B1 publication Critical patent/KR102932817B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227001501A 2019-06-19 2020-06-17 인간 면역결핍 바이러스 복제의 억제제로서의 피리도[2,3-d]피리미딘 유도체 Active KR102932817B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962863406P 2019-06-19 2019-06-19
US62/863,406 2019-06-19
PCT/IB2020/055653 WO2020254985A1 (en) 2019-06-19 2020-06-17 Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication

Publications (2)

Publication Number Publication Date
KR20220024608A KR20220024608A (ko) 2022-03-03
KR102932817B1 true KR102932817B1 (ko) 2026-03-04

Family

ID=71738195

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227001501A Active KR102932817B1 (ko) 2019-06-19 2020-06-17 인간 면역결핍 바이러스 복제의 억제제로서의 피리도[2,3-d]피리미딘 유도체

Country Status (33)

Country Link
US (2) US12129255B2 (https=)
EP (1) EP3986561B1 (https=)
JP (1) JP7628512B2 (https=)
KR (1) KR102932817B1 (https=)
CN (2) CN114245795B (https=)
AR (1) AR119174A1 (https=)
AU (1) AU2020295793B2 (https=)
BR (1) BR112021025655A2 (https=)
CL (1) CL2021003388A1 (https=)
CO (1) CO2021017479A2 (https=)
CR (1) CR20210664A (https=)
DK (1) DK3986561T3 (https=)
ES (1) ES2974541T3 (https=)
FI (1) FI3986561T3 (https=)
HR (1) HRP20240501T1 (https=)
HU (1) HUE065762T2 (https=)
IL (1) IL288750B2 (https=)
LT (1) LT3986561T (https=)
MA (1) MA56526B1 (https=)
MD (1) MD3986561T2 (https=)
MX (1) MX2021016149A (https=)
MY (1) MY206712A (https=)
PE (1) PE20220510A1 (https=)
PH (1) PH12021553180A1 (https=)
PL (1) PL3986561T3 (https=)
PT (1) PT3986561T (https=)
RS (1) RS65304B1 (https=)
SI (1) SI3986561T1 (https=)
SM (1) SMT202400153T1 (https=)
TW (1) TWI850403B (https=)
UA (1) UA128967C2 (https=)
UY (1) UY38755A (https=)
WO (1) WO2020254985A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11541055B2 (en) 2018-10-24 2023-01-03 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
BR112021025637A2 (pt) 2019-06-19 2022-02-01 Nmd Pharma As Compostos para o tratamento de doenças neuromusculares
BR112021025655A2 (pt) 2019-06-19 2022-02-01 Viiv Healthcare Uk No 5 Ltd Inibidores da replicação do vírus da imunodeficiência humana
MX2022003945A (es) * 2019-10-01 2022-04-25 Viiv Healthcare Co Metodo para tratar vih con cabotegravir y rilpivirina.
JP7703538B2 (ja) * 2019-12-09 2025-07-07 ヴィーブ、ヘルスケア、カンパニー カボテグラビルを含んでなる医薬組成物
KR20220151655A (ko) * 2020-03-06 2022-11-15 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제
BR112022020933A2 (pt) * 2020-04-15 2022-12-06 Viiv Healthcare Uk No 5 Ltd Inibidores de replicação do vírus da imunodeficiência humana
MX2024004551A (es) * 2021-10-13 2024-06-26 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicacion del virus de inmunodeficiencia humana.
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
CN121335877A (zh) 2023-06-15 2026-01-13 Viiv保健英国第五有限公司 用于制备化合物的方法和中间体
TW202547514A (zh) 2024-02-05 2025-12-16 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018203235A1 (en) 2017-05-02 2018-11-08 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1363705B9 (en) 2001-02-02 2012-11-07 Bristol-Myers Squibb Company Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
PL2212324T3 (pl) * 2008-07-02 2014-11-28 Avexa Ltd Związki posiadające właściwości przeciwwirusowe
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
AU2012278976B2 (en) 2011-07-06 2017-05-11 Gilead Sciences, Inc. Compounds for the treatment of HIV
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
ES2642265T3 (es) 2013-01-09 2017-11-16 Gilead Sciences, Inc. Compuestos terapéuticos para el tratamiento de infecciones virales
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
TW201443037A (zh) * 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
EP3186239B1 (en) 2014-08-29 2018-10-10 Gilead Sciences, Inc. Antiretroviral agents
CN119462611A (zh) 2016-08-19 2025-02-18 吉利德科学公司 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物
WO2018045150A1 (en) * 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
US11541055B2 (en) * 2018-10-24 2023-01-03 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
UY38559A (es) * 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
BR112021025655A2 (pt) 2019-06-19 2022-02-01 Viiv Healthcare Uk No 5 Ltd Inibidores da replicação do vírus da imunodeficiência humana

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018203235A1 (en) 2017-05-02 2018-11-08 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Also Published As

Publication number Publication date
AR119174A1 (es) 2021-12-01
UA128967C2 (uk) 2024-12-11
MA56526B1 (fr) 2024-05-31
CN119039288A (zh) 2024-11-29
CN114245795A (zh) 2022-03-25
DK3986561T3 (da) 2024-03-04
UY38755A (es) 2020-11-30
US20210323967A1 (en) 2021-10-21
JP7628512B2 (ja) 2025-02-10
MX2021016149A (es) 2022-05-18
CA3143136A1 (en) 2020-12-24
ES2974541T3 (es) 2024-06-27
PE20220510A1 (es) 2022-04-07
PT3986561T (pt) 2024-03-15
JP2022537047A (ja) 2022-08-23
US20250019383A1 (en) 2025-01-16
IL288750B2 (en) 2025-04-01
IL288750B1 (en) 2024-12-01
HUE065762T2 (hu) 2024-06-28
CL2021003388A1 (es) 2022-09-30
EP3986561A1 (en) 2022-04-27
KR20220024608A (ko) 2022-03-03
LT3986561T (lt) 2024-04-25
RS65304B1 (sr) 2024-04-30
MY206712A (en) 2025-01-03
CN114245795B (zh) 2024-08-06
TWI850403B (zh) 2024-08-01
FI3986561T3 (fi) 2024-05-02
WO2020254985A1 (en) 2020-12-24
EP3986561B1 (en) 2024-02-14
PH12021553180A1 (en) 2022-11-07
PL3986561T3 (pl) 2024-06-10
CO2021017479A2 (es) 2022-04-19
MA56526A (fr) 2022-04-27
HRP20240501T1 (hr) 2024-07-05
SI3986561T1 (sl) 2024-04-30
US12129255B2 (en) 2024-10-29
AU2020295793B2 (en) 2023-07-06
SMT202400153T1 (it) 2024-05-14
IL288750A (en) 2022-02-01
CR20210664A (es) 2022-01-21
BR112021025655A2 (pt) 2022-02-01
AU2020295793A1 (en) 2022-01-20
TW202115055A (zh) 2021-04-16
MD3986561T2 (ro) 2024-06-30

Similar Documents

Publication Publication Date Title
KR102932817B1 (ko) 인간 면역결핍 바이러스 복제의 억제제로서의 피리도[2,3-d]피리미딘 유도체
EP3917930B1 (en) Inhibitors of human immunodeficiency virus replication
JP7799620B2 (ja) ヒト免疫不全ウイルス複製の阻害剤
JP7545414B2 (ja) ヒト免疫不全ウイルス複製阻害剤
US20230106880A1 (en) Inhibitors of human immunodeficiency virus replication
RU2804033C2 (ru) Ингибиторы репликации вируса иммунодефицита человека
CA3143136C (en) Pyrido[2,3-d]pyrimidine derivatives as capsid inhibitors for treating human immunodeficiency virus
HK40066649A (en) Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
HK40066649B (en) Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication
EA044806B1 (ru) Ингибиторы репликации вируса иммунодефицита человека
BR122024007306A2 (pt) Composição farmacêutica que compreende o composto da fórmula ia, fórmula ib, fórmula ic ou fórmula id e uso da mesma para tratamento de infecção por hiv

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)